Sentinel node biopsy in breast cancer — the ALMANAC trial

Clarke, Daniel H.; Khonji, N.; Sweetland, Helen; Evans, W. D.; Rees, J. B. Van; Mansel, Robert Edward

doi:10.1016/s0959-8049(99)81244-1

Cited by 13 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Trial methodology will need modification—for example, to show completion of the curve before beginning randomisation, w32 as in two recent trials. 29 30 In theory, patients could also be randomised not to operations but to surgeons, who would perform their operation of preference, although this option remains untested in practice.…”

Section: Proposed Solutionsmentioning

confidence: 99%

Randomised trials in surgery: problems and possible solutions

McCulloch

Taylor²,

Sasako³

et al. 2002

BMJ

663

473

View full text Add to dashboard Cite

Section: Proposed Solutionsmentioning

confidence: 99%

Randomised trials in surgery: problems and possible solutions

McCulloch

Taylor²,

Sasako³

et al. 2002

BMJ

663

473

View full text Add to dashboard Cite

“…Sentinel lymph node (SLN) biopsy is a minimally invasive and accurate method of axillary staging in breast cancer1. Large‐scale randomized controlled trials evaluating SLN biopsy are under way2, 3. However, the optimal mapping technique remains controversial4.…”

Section: Introductionmentioning

confidence: 99%

Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer

Hung

Chan

Ying

et al. 2005

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…[5][6][7] Several randomized controlled trials are underway to compare SLNB with axillary dissection and the results are eagerly awaited. 8,9 In patients with negative sentinel lymph nodes (SLN), no further treatment to the axilla may be required and the morbidities of axillary dissection could be avoided. In patients with positive sentinel nodes, axillary dissection is indicated to remove any residual metastatic lymph nodes in the axilla.…”

Section: Introductionmentioning

confidence: 99%

Non‐sentinel lymph node metastases in breast cancer patients with metastatic sentinel nodes

Hung¹,

Chan²,

Mak³

et al. 2005

ANZ Journal of Surgery

View full text Add to dashboard Cite

Purpose: Metastatic breast cancer is a leading cause of mortality in women, partly on account of brain metastases. However, the mechanisms by which cancer cells cross the blood-brain barrier remain undeciphered. Most molecular studies predicting metastatic risk have been performed on primary breast cancer samples. Here we studied metastatic lymph-nodes from patients with breast cancers to identify markers associated with the occurrence of brain metastases. Results: Transcriptomic analyses identified CDKN2A/p16 as a gene potentially associated with brain metastases. Materials and Methods: Fifty-two patients with HER2-overexpressing or triple-negative breast carcinoma with lymph nodes and distant metastases were included in this study. Transcriptomic analyses were performed on laser-microdissected tumor cells from 28 metastatic lymph-nodes. Supervised analyses compared the transcriptomic profiles of women who developed brain metastases and those who did not. As a validation series, we studied metastatic lymph-nodes from 24 other patients. Immunohistochemistry investigations showed that p16 mean scores were significantly higher in patients with brain metastases than in patients without (7.4 vs. 1.7 respectively, p < 0.01). This result was confirmed on the validation series. Multivariate analyses showed that the p16 score was the only variable positively associated with the risk of brain metastases (p = 0.01).

show abstract

Sentinel node biopsy in breast cancer — the ALMANAC trial

Cited by 13 publications

References 0 publications

Randomised trials in surgery: problems and possible solutions

Randomised trials in surgery: problems and possible solutions

Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer

Non‐sentinel lymph node metastases in breast cancer patients with metastatic sentinel nodes

Contact Info

Product

Resources

About